Premium
Management of submucous uterine fibroid with buserelin, gemeprost and hysteroscopic resection
Author(s) -
Lawrence Anthony S,
Healy David L,
Hill David,
Paterson Peter J
Publication year - 1991
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1991.tb121094.x
Subject(s) - medicine , buserelin , hysteroscopy , ureterolysis , uterine fibroids , hysterectomy , surgery , electrosurgery , agonist , urinary system , receptor , hydronephrosis , endocrinology
A 19‐year‐old virgin presented with severe menorrhagia and a haemoglobin level of 76 giL as a problem of management. A 5 cm diameter submucous fibroid was identified at hysteroscopy and biopsied but was unable to be removed. The luteinising hormone releasing hormone agonist, buserelin, was used in an attempt to produce symptomatic relief. One week after commencing buserelin therapy, severe menorrhagia occurred and the patient was admitted to hospital with a haemoglobin concentration of 24 giL. Buserelin treatment was continued and no further menstruation occurred over he following year. As the patient was now well, hysteroscopic submucous fibroid resection was contemplated. Due to cervical rigidity in this teenager, a 1 mg gemeprost pessary was inserted into the posterior vaginal fornix three hours before surgery. This allowed an operative hysteroscope to be inserted into the uterus and a fibroid resection to be performed. Menstrual blood loss has been normal for six months after hysteroscopy. A combined medical and surgical approach may avoid hysterectomy in such problem patients.